According to Harvard Bioscience's latest financial reports and stock price the company's current Operating Margin is -13.66%. At the end of 2023 the company had an Operating Margin of -2.28%.
Year | Operating Margin | Change |
---|---|---|
2023 | -2.28% | -71.88% |
2022 | -8.10% | 6778.6% |
2021 | -0.12% | -98.35% |
2020 | -7.14% | 50.81% |
2019 | -4.74% | -28.28% |
2018 | -6.60% | 95.02% |
2017 | -3.39% | 14.98% |
2016 | -2.94% | -11.31% |
2015 | -3.32% | -181.68% |
2014 | 4.06% | 882.77% |
2013 | 0.41% | -93.33% |
2012 | 6.20% | -1.73% |
2011 | 6.31% | -28.63% |
2010 | 8.84% | -22.72% |
2009 | 11.44% | 31.67% |
2008 | 8.69% | -24.26% |
2007 | 11.47% | 4.09% |
2006 | 11.02% | 4.08% |
2005 | 10.59% | -10.18% |
2004 | 11.79% | 41.96% |
2003 | 8.30% | 102.95% |
2002 | 4.09% | -148.92% |
2001 | -8.36% |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.